Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rimonabant Sanofi-Synthélabo.

Jose R Fernandez1, David B Allison

  • 1University of Alabama at Birmingham, Department of Nutrition Sciences, Ryals Public Health Building, 1665 University Blvd, Birmingham, AL 35294-0022, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|May 12, 2004
PubMed
Summary

Rimonabant, a CB1 receptor antagonist, is being investigated for obesity and smoking cessation. Clinical trials for both indications were in Phase III by September 2003, indicating ongoing development for these therapeutic areas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eating versus skipping breakfast has no discernible effect on obesity-related anthropometric outcomes: a systematic review and meta-analysis.

F1000Research·2023
Same author

Aging: What We Can Learn From Elephants.

Frontiers in aging·2022
Same author

Risk of Type 2 Diabetes Among Individuals with Excess Weight: Weight Trajectory Effects.

Current diabetes reports·2022
Same author

Errors and incorrect conclusions need correction in "The low-carbohydrate-diet score is associated with resting metabolic rate: an epidemiologic study among Iranian adults".

Journal of diabetes and metabolic disorders·2022
Same author

Estimation of sparse functional quantile regression with measurement error: a SIMEX approach.

Biostatistics (Oxford, England)·2022
Same author

Taking a Hard Look at the Empirical Evidence for Popular Community-Based Interventions in Obesity.

JAMA pediatrics·2022

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Drug Development

Background:

  • Rimonabant targets central cannabinoid type 1 (CB1) receptors.
  • It is being developed by Sanofi-Synthélabo.
  • Potential therapeutic applications include obesity and smoking cessation.

Purpose of the Study:

  • To evaluate the efficacy and safety of Rimonabant.
  • To assess Rimonabant's potential as a treatment for obesity.
  • To determine Rimonabant's utility as a smoking cessation agent.

Main Methods:

  • Phase III clinical trials were conducted.
  • Trials were initiated for obesity in August 2001.
  • Trials for smoking cessation commenced by September 2002.

Main Results:

  • Phase III trials for obesity were ongoing as of September 2003.
  • Phase III trials for smoking cessation were also ongoing as of September 2003.
  • The ongoing nature of Phase III trials suggests continued investigation into Rimonabant's therapeutic potential.

Conclusions:

  • Rimonabant development for obesity and smoking cessation was actively progressing through Phase III trials in 2003.
  • Further data from these trials were anticipated to determine the drug's ultimate clinical utility.

Related Experiment Videos